Related Experiment Video
Updated: Jul 10, 2026

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
Published on: May 12, 2023
Agents under investigation for the treatment and prevention of neutropenia
1University of Rochester, James P Wilmot Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA.
Abstract:
Neutropenia, and most notably febrile neutropenia, represents a significant complication following chemotherapy administration. Present agents used for the treatment of neutropenia include G-CSF, GM-CSF and G-CSF conjugated to polyethylene glycol (PEG) as pegylated G-CSF. Despite the availability and considerable efficacy of the above approved agents in reducing the risk of neutropenia and its complications remain significant issues in oncology. This article explores some of the biology behind the colony-stimulating factors and the recent advances in agents for the treatment and prevention of neutropenia, including the development of additional G-CSF agonists, chemoprotectants, retinoic receptor agonists and CXC chemokine receptor 4 antagonists.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Treatment Resistent Cancers
Treatment Resistant Cancers
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
